Skip to main content
Fig. 3 | Genome Medicine

Fig. 3

From: Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients

Fig. 3

SHARC identifies and validates tumor-specific SV biomarkers from low-pass nanopore tumor sequencing data. Plots showing the distribution of a coverage and b read length for the nine tumor samples sequenced on one flow cell each. Dashed lines represent averages for each sample. c Total number of somatic SVs present at each of the steps throughout the SV calling and filtering pipeline. RF, random forest; DBFilter, database filter. d The Top20 ranked breakpoints for each sample were tested by breakpoint PCR using tumor and germline DNA. The graph depicts the number of breakpoints validated as somatic (blue), germline (green), or breakpoints that could not be validated (red)

Back to article page